Flyers/Resources to Distribute:
- Sarasota for Vaccination Choice NEW
- Dr. Blaylock & Dr. Mercola Debunk the H1N1 "Pandemic"
- Educate Yourself re: Mass-Vaccination (tri-fold, PDF)
- ** FLORIDA SWINE FLU VACCINE LAWSUIT!
- The Truth about Flu Shots in Pregnancy
- FDA Vaccine Package Inserts: 3 Injectable, 1 Intranasal: PDF's Here
- Swine Flu Arrives in Sarasota: Examining H1N1 'Swine Flu' and the Government's Rush to Vaccinate
- 2009 Florida Statutes: 381.00315 Public health advisories; public health emergencies
- Nuremberg Code: Directives for Human Experimentation
- Adverse Effects of Adjuvants in Vaccines
- Refuse and Resist Mandatory Flu Vaccines
Wednesday, September 16, 2009
Package Insert - Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur, Inc.) (PDF - 228KB)
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182404.pdf
Sarasota for Vaccination Choice Comment:
Read the fine print, the devil is in the details?
NOTE: This is one of three INJECTABLE H1N1 Vaccines approved by FDA on Sept. 15, 2009. FDA also approved one Intranasal vaccine.
=========
Package Insert - Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur, Inc.) (PDF - 228KB)
EXCERPT:
<<<
11. DESCRIPTION
Influenza A (H1N1) 2009 Monovalent Vaccine, an inactivated influenza virus vaccine, for intramuscular use, is prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.
Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/ California/07/2009 (H1N1) v-like virus per 0.5 mL dose. Gelatin 0.05% is added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg), polyethylene glycol p-isooctylphenyl ether (not more than 0.02%), and sucrose (not more than 2.0%).
There is no thimerosal used in the manufacturing process of the single-dose presentations of Influenza A (H1N1) 2009 Monovalent Vaccine. The multi-dose presentation of Influenza A (H1N1) 2009 Monovalent Vaccine contains thimerosal, a mercury derivative, added as a preservative. Each 0.5 mL dose of the multidose presentation contains 25 mcg mercury.
Influenza A (H1N1) 2009 Monvalent Vaccine is a sterile clear to a slightly opalescent suspension.
Antibiotics are not used in the manufacture of Influenza A (H1N1) 2009 Monovalent Vaccine.
All presentations of Influenza A (H1N1) 2009 Monovalent Vaccine do not contain latex.
>>>
Sarasota for Vaccination Choice Comment:
Read the fine print, the devil is in the details?
NOTE: This is one of three INJECTABLE H1N1 Vaccines approved by FDA on Sept. 15, 2009. FDA also approved one Intranasal vaccine.
=========
Package Insert - Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur, Inc.) (PDF - 228KB)
EXCERPT:
<<<
11. DESCRIPTION
Influenza A (H1N1) 2009 Monovalent Vaccine, an inactivated influenza virus vaccine, for intramuscular use, is prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.
Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/ California/07/2009 (H1N1) v-like virus per 0.5 mL dose. Gelatin 0.05% is added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg), polyethylene glycol p-isooctylphenyl ether (not more than 0.02%), and sucrose (not more than 2.0%).
There is no thimerosal used in the manufacturing process of the single-dose presentations of Influenza A (H1N1) 2009 Monovalent Vaccine. The multi-dose presentation of Influenza A (H1N1) 2009 Monovalent Vaccine contains thimerosal, a mercury derivative, added as a preservative. Each 0.5 mL dose of the multidose presentation contains 25 mcg mercury.
Influenza A (H1N1) 2009 Monvalent Vaccine is a sterile clear to a slightly opalescent suspension.
Antibiotics are not used in the manufacture of Influenza A (H1N1) 2009 Monovalent Vaccine.
All presentations of Influenza A (H1N1) 2009 Monovalent Vaccine do not contain latex.
>>>
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment